CRVS vs TPVG

TriplePoint Venture Growth BDC Corp.

(TPVG) offers the better valuation at 4. 6x trailing P/E (6. 0x forward), making it the more compelling value choice. Analysts rate Corvus Pharmaceuticals, Inc. (CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +425. 5%, compared to -19. 0% for TriplePoint Venture Growth BDC Corp. (TPVG). Over 10 years, the gap is even starker: TPVG returned +87. 8% versus CRVS's +27. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TriplePoint Venture Growth BDC Corp.

(TPVG) is the lower-risk stock at 0. 83β versus Corvus Pharmaceuticals, Inc. 's 1. 63β — meaning CRVS is approximately 96% more volatile than TPVG relative to the S&P 500. On balance sheet safety, Corvus Pharmaceuticals, Inc. (CRVS) carries a lower debt/equity ratio of 2% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: TriplePoint Venture Growth BDC Corp.

grew EPS 48. 8% year-over-year, compared to 48. 0% for Corvus Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus 0. 0% for Corvus Pharmaceuticals, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus 0. 0% for CRVS. At the gross margin level — before operating expenses — TPVG leads at 83. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CRVS: 114.

7% to $33. 17.

In this comparison, TPVG (18.

4% yield) pays a dividend. CRVS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83), 18. 4% yield). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TPVG: +87. 8%, CRVS: +27. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CRVS (Healthcare) and TPVG (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CRVS is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock. TPVG pays a dividend while CRVS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.